Yamada Shinsuke, Hayashi Noriyuki, Toi Norikazu, Miyaoka Daichi, Hashimoto Motomu
Clinical Immunology, Osaka Metropolitan University of Medicine, Osaka, JPN.
Internal Medicine, Ohno Memorial Hospital, Osaka, JPN.
Cureus. 2024 Jul 19;16(7):e64900. doi: 10.7759/cureus.64900. eCollection 2024 Jul.
Pregnancy and lactation-associated osteoporosis (PLO) is one of the rarest and most serious primary osteoporotic conditions that develops during the third trimester of gestation and/or early postpartum period. A history of PLO often causes individuals to hesitate when considering an additional child due to anxiety about recurrence risk. Reported here are details of a 29-year-old patient with PLO given aggressive treatment for osteoporosis with teriparatide who subsequently gave birth to a healthy child at age 33 without PLO recurrence. Further case studies are needed to examine the efficacy and safety of PLO treatment and to provide beneficial results for those who wish to have another pregnancy.
妊娠和哺乳期相关骨质疏松症(PLO)是最罕见、最严重的原发性骨质疏松症之一,发生在妊娠晚期和/或产后早期。PLO病史常常使患者在考虑再要一个孩子时犹豫不决,因为担心复发风险。本文报告了一名29岁PLO患者的详细情况,该患者接受了特立帕肽积极治疗骨质疏松症,随后在33岁时生下一个健康的孩子,且PLO未复发。需要进一步的病例研究来检验PLO治疗的有效性和安全性,并为那些希望再次怀孕的人提供有益的结果。